Biocon Limited, an innovation-led global biopharmaceutical company, on Monday announced the launch of its Glucagon-like Peptide-1 (GLP-1) therapy, Liraglutide, in the Netherlands for the treatment of diabetes and obesity.
The drug-device combination will be marketed through its distribution partner, Pharmamedic B.V., under the brand names Diavorin® for diabetes (gVictoza®) and Vobexoryn® for chronic weight management (gSaxenda®). The launch follows approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year.
This marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand, representing a key milestone in the company’s European expansion strategy.
Commenting on the development, Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Limited, said the launch strengthens Biocon’s GLP-1 portfolio across global markets and underscores the strategic importance of peptide-based therapies. He added that Biocon’s vertically integrated capabilities enable it to deliver high-quality, affordable metabolic treatments at scale, while reinforcing its commitment to expanding access to advanced therapies for diabetes and obesity and supporting sustainable healthcare systems globally.